Atsena Therapeutics

company

About

Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$55M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Atsena has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$63.15M
Atsena Therapeutics has raised a total of $63.15M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 16, 2020 Series A $55M 1 Detail
Apr 1, 2020 Series A $8.15M 1 Foundation Fighting Blindness Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Atsena Therapeutics is funded by 2 investors. Foundation Fighting Blindness and Retinal Degeneration Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Foundation Fighting Blindness Yes Series A
Retinal Degeneration Fund Series A